These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 9364672)

  • 41. Plant-derived H7 VLP vaccine elicits protective immune response against H7N9 influenza virus in mice and ferrets.
    Pillet S; Racine T; Nfon C; Di Lenardo TZ; Babiuk S; Ward BJ; Kobinger GP; Landry N
    Vaccine; 2015 Nov; 33(46):6282-9. PubMed ID: 26432915
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
    Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants.
    Valensi JP; Carlson JR; Van Nest GA
    J Immunol; 1994 Nov; 153(9):4029-39. PubMed ID: 7930610
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.
    de Wit E; Munster VJ; Spronken MI; Bestebroer TM; Baas C; Beyer WE; Rimmelzwaan GF; Osterhaus AD; Fouchier RA
    J Virol; 2005 Oct; 79(19):12401-7. PubMed ID: 16160167
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immune response and protection against influenza A infection in mice immunised with subunit influenza A vaccine in combination with whole cell or acellular DTP vaccine.
    Tamizifar H; Robinson A; Jennings R; Potter CW
    Vaccine; 1995 Nov; 13(16):1539-46. PubMed ID: 8578839
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MF59-adjuvanted and virosomal influenza vaccines for preventing influenza hospitalization in older people: comparative effectiveness using the Valencia health care information system.
    Puig-Barberà J; Natividad-Sancho A; Calabuig-Pérez J; Lluch-Rodrigo JA; Pastor-Villalba E; Martínez-Úbeda S; Pérez-Vilar S; Díez-Domingo J
    Vaccine; 2013 Aug; 31(37):3995-4002. PubMed ID: 23731629
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza A subunit vaccine using various adjuvants.
    Benne CA; Harmsen M; van der Graaff W; Verheul AF; Snippe H; Kraaijeveld CA
    Vaccine; 1997 Jun; 15(9):1039-44. PubMed ID: 9261954
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.
    Del Giudice G; Hilbert AK; Bugarini R; Minutello A; Popova O; Toneatto D; Schoendorf I; Borkowski A; Rappuoli R; Podda A
    Vaccine; 2006 Apr; 24(16):3063-5. PubMed ID: 16464520
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
    Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
    Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(2):365-72. PubMed ID: 16035948
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.
    Nicholson KG; Colegate AE; Podda A; Stephenson I; Wood J; Ypma E; Zambon MC
    Lancet; 2001 Jun; 357(9272):1937-43. PubMed ID: 11425416
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A dose-ranging study of MF59(®)-adjuvanted and non-adjuvanted A/H1N1 pandemic influenza vaccine in young to middle-aged and older adult populations to assess safety, immunogenicity, and antibody persistence one year after vaccination.
    Reisinger KS; Holmes SJ; Pedotti P; Arora AK; Lattanzi M
    Hum Vaccin Immunother; 2014; 10(8):2395-407. PubMed ID: 25424947
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines.
    Liu H; Bungener L; ter Veer W; Coller BA; Wilschut J; Huckriede A
    Vaccine; 2011 Mar; 29(11):2037-43. PubMed ID: 21251903
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Efficacy of A/H1N1/2009 split inactivated influenza A vaccine (GC1115) in mice and ferrets.
    Han HJ; Song MS; Park SJ; Byun HY; Robles NJC; Ha SH; Choi YK
    J Microbiol; 2019 Feb; 57(2):163-169. PubMed ID: 30706345
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.
    Hatz C; Cramer JP; Vertruyen A; Schwarz TF; von Sonnenburg F; Borkowski A; Lattanzi M; Hilbert AK; Cioppa GD; Leroux-Roels G
    Vaccine; 2012 Jul; 30(32):4820-7. PubMed ID: 22626675
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
    Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
    Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Influenza vaccination in children primed with MF59-adjuvanted or non-adjuvanted seasonal influenza vaccine.
    Vesikari T; Forstén A; Arora A; Tsai T; Clemens R
    Hum Vaccin Immunother; 2015; 11(8):2102-12. PubMed ID: 26091244
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.